Introduction
Since the late discovery of the first sulfoximine compound in 1949, [1] sulfoximine chemistry [2] has been ar ather niche discipline, explored by only af ew research groups worldwide. Applications have mainly centered around the use of sulfoximines as either chiral auxiliaries [3] or ligands in asymmetricc atalysis.
[4]
Satzinger and Stoss at Gçdecke AG pioneered the use of the sulfoximine group in medicinal chemistry in the 1970s. [5] However,u ntil very recently,t he sulfoximine group has rarely been employed in drug discovery applications, even though it offers au nique combination of interesting properties, namely high chemicala nd metabolic stability, favorable physicochemical properties, hydrogen-bond acceptor/donor functionalities, and structurald iversity. [6] To date, there is no approved drug containing as ulfoximine group and the number of sulfoximine compounds evaluated in clinicalt rials has been very limited. A similar pictureh as emergedi nc rop protection applications; however, use of the sulfoximine insecticide sulfoxaflor wasa pprovedin2 013. [7] Low commercial availability and limited available synthetic methods with associatedsafety concerns [8] have likely hindered the use of the sulfoximine group historically,e specially in industry.H owever,o ver the last decade, activity in sulfoximine chemistry has increased considerably,l eadingt on ew and safe synthetic methods.
[9] Developments of late include, for instance,t he use of flow chemistry techniques, [10] the palladiumcatalyzed direct a-arylation of protected S,S-dimethylsulfoximine, [11] and the first methodf or the direct synthesisofN H-sulfoximines from sulfides. [12] This progress in synthetic methodology has coincided with the rapidlyincreasing interestins ulfoximinesa sp harmacophores in the life sciences. [13] In drug discovery,t he clinicalk inase inhibitors for the treatment of cancer,r oniciclib, [13b, 14] BAY1 143572, [15] and AZD 6738, [16] have been the focus of considerable attention recently ( Figure 1) .
Even though the interestw as rather limited for many decades, research has been conducted in which the sulfoximine group was used in opportunistic approaches to replace as urprising variety of functional groups including alcohol, acid, amidine, sulfone, ands ulfonamide moieties. [6] Very recently,the physicochemical properties and behavior in selected in vitro assays of as et of small and fragment-like sulfoximines in comparisonw ith related sulfur-based analogues and amides has been reported. [17] To overcome the limitations of analyzing such small and fragment-like compounds,t hat study also contained am atched molecularp air analysis of sulfoximinesa nd relatedc ompounds from drug discovery projects at Boehringer Ingelheim. However,t his qualitative analysis did not disclose the corresponding chemical structuresa nd assay data.
During the course of our long-standing interest in sulfoximines as an underrepresented pharmacophore in drug discovery, [18] we have investigated av ariety of approaches which were not intendedt oi dentify clinicalc andidates but to improve our general understandingo ft he sulfoximine functional group with respect to synthesis [11] and medicinal chemistry relevant properties. One idea was to synthesize direct sulfoximine analogues of marketed drugs or advanced clinicalc andidates to compare the in vitro properties of the matched molecular pairs. Our selection of the corresponding target molecules was mainly triggered by synthetic opportunity,o ur general interest Sulfoximines have gained considerable recognition as an important structural motif in drug discoveryo fl ate. In particular, the clinical kinase inhibitors for the treatment of cancer,r oniciclib (pan-CDK inhibitor), BAY1 143572 (P-TEFb inhibitor), and AZD 6738( ATRi nhibitor), have recently drawn considerable attention.W hilst the interesti nt his underrepresented functional group in drug discovery is clearly on the rise, there remains an incomplete understanding of the medicinal-chemistry-relevant properties of sulfoximines. Herein we report the synthesis and in vitro characterization of av ariety of sulfoximine analogues of marketed drugs and advanced clinical candidates to gain ab etter understanding of this neglected functional group and its potential in drug discovery.
in kinase inhibitors, and/or the possibility of evaluatingt he test compounds in readily availablea ssays.M oreover,w ew ere also interested in investigating the effects of the replacement of non-sulfur-based functional groups, such as amines which are ubiquitous in life science approaches, by sulfoximines. Herein, we report the synthesis and in vitro characterization of six sulfoximine analogues of marketed drugs (imatinib, palbociclib, vardenafil, fulvestrant) and advanced clinicalc andidates (AT7519, ribociclib).
Results and Discussion
Imatinib Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers. Targeted therapy in the form of selectivet yrosine kinase inhibitors has transformed the approach for the management of various cancers and represents at herapeutic breakthrough. Imatinibm esylate, an oral smallmolecule inhibitor of several tyrosine kinases, including ABL, KIT,a nd PDGFR, was one of the first cancert herapies to show the potentialf or such targeted action. [19] Imatinib, the standard of care in chronic myelogenous leukemia and certain gastrointestinal stromal tumors, has dramatically changed the outlook of patients affected by these diseases.
The chemical structure of imatinib contains ap olar side chain, an N-methylpiperazinyl moiety (Figure 2 ), that markedly improves both solubility and oral bioavailability. [20] Under physiological conditions, the piperazinyl group is predominantly protonated and imatinibc arries an et positive chargei nt he bound complex with tyrosine kinases.T his enables hydrogenbondingi nteractions between imatinib and the backbonec arbonyl of specific residues in the binding pocket. [21] Moreover, imatinib is primarily metabolized at the N-methylpiperazinyl moiety to an active metabolite, the N-demethylated piperazine derivative. [22] The introductiono fw ater-solubilizing groups, such as morpholinyl, piperazinyl, piperidinyl, and acyclic tertiarya mino, at positionst hat projectt oward solvent, andt herefore do not compromise inhibitory potency, is ac ommon approach for improvingt he physicochemical properties of kinase inhibitors. [23] However, the introduction of basic solubilizing groups can also greatly affectA DME properties such as permeability,m etabolic stability, absorption, clearance, oral bioavailability,a nd target organ exposure. It also bears an umber of risks with respect to toxicity,i ncluding higher affinity for hERG channels with associated risks of QT prolongation, induction of phospholipidosis, and/or potentialfor increased off-target activity. [24] In an opportunistic approach, we wondered if 1l 6 -thiomorpholine-1-imine 1-oxide could serve as as tructurala lternative for the N-methylpiperazine group [25] in imatinib, originally incorporated into the molecule to improves olubility.L ike the protonated N-methylpiperazine group, the sulfoximine group is tetrahedral and hasb een described as offering favorable physicochemistry in conjunction with good DMPK properties. Moreover,t he sulfoximine group has dual hydrogen-bond donor/acceptor functionality,b ut significantly decreased basicity. [6, 17] The required sulfoximine building block 4 was synthesized in four steps from thiomorpholine. Thus, the amino group was first conveniently protected by reactionw ithb enzylc hloroformate (CbzCl). Then, oxidation of the resulting sulfide 1 to sulfoxide 2,f ollowedb yr hodium-catalyzed imination with 2,2,2-trifluoroacetamide, [9a] afforded sulfoximine 3,w hich wasf inally Figure 2. Structure of imatinib with its proposed binding mode to tyrosine kinase, [26] and structureo fs ulfoximine analogue 8.
subjected to hydrogenolysis to remove the Cbz group (Scheme 1). The amide partner 6 was then preparedi nq uantitative yield by coupling of the commercial building block 5 and4 -(chloromethyl)benzoyl chloride (Scheme 2). Subsequentr eactiono f benzylc hloride 6 with amine 4,f ollowed by removal of the trifluorocarbonyl group attachedt ot he sulfoximine nitrogen in 7 under basic conditions, afforded the desired imatinib sulfoximine analogue 8.
Relative to the reported quantitative dissociation constants (K d )o fi matinib, [27] sulfoximine analogue 8 exhibited reduced binding to non-phosphorylated ABL1 (imatinib K d = 1.1 nm vs. . This modulated selectivity profile of analogue 8 is quite surprising, since the sulfoximine group of the bound inhibitor is also expectedt ob ed irected toward the exit of the ATPb inding pocket.
Aqueous solubility (S w )o fb oth compounds at pH 6.5 was determined by an orienting, high-throughput screening method using 1mm DMSO stock solutions. [28] Imatinibh as an aqueous solubility of 112mgL
À1
,c omparedw ith 54 mg L À1 for analogue 8.S imilarl ogD values at pH 7.5 for imatinib (1.9) and for analogue 8 (2.0) were recorded by using am ethodf or determining hydrophobicity constants by reversed-phase HPLC [29] ( Table 1) .
In vitro pharmacokinetic studies with imatinib and sulfoximine analogue 8 revealed at rend for as lightly improved metabolic stability of 8 in rat hepatocytes, resultingi namoderate predicted blood clearance (CL b and am oderate efflux ratio of 2.7 (Table 1) .
With rather similar solubility at pH 6.5, as determined in the high-throughput screeningm ethod, and very similar logD value,t he pronouncedd ecrease in permeability and increased efflux ratio of sulfoximineanalogue 8 relative to imatinib is surprising. The structuralc hange from the N-methylpiperazine group to the 1l 6 -thiomorpholine-1-imine 1-oxide analogue results in an increased topological polar surface area( TPSA) and molecular weight (see Table 6b elow). An additional hydrogenbond donor is also introduced.N evertheless, the TPSA of 123.96 andt he number of hydrogen-bond donors (three) and acceptors (eight) of analogue 8 is still within most of the generally accepted drug-like score rules. [31] Only its molecular Scheme2.Synthesis of imatinib analogue 8. Reagentsa nd conditions:a)4-(chloromethyl)benzoyl chloride (1.1 equiv),K 2 CO 3 (2.1 equiv), THF,08C, 2h,t hen RT, 2h,9 9%;b )4 (1.5 equiv), Et 3 N( 2equiv), DMF,150 8C, 24 h; c) K 2 CO 3 (2 equiv), MeOH, RT,1h, 5% (2 steps). [28] [d] Determined by reversed-phaseH PLC. [29] [e]Predicted hepatic metabolic clearance based on ah igh-throughputm etabolic stability assay using 1) freshly harvestedr at hepatocytes( rHep) and 2) pooled human liver microsomes (hLMs). [30] [f] P app A!B( apical to basolateral) and efflux ratio (ER) data were generated in ab idirectionally performed Caco2 permeability assay in a2 4-well format;ERw as calculated as P app B!A/P app A!B. [30] ChemMedChem 2017, 12,487 -501 www.chemmedchem.org 2017 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim weighto f5 27.64 Dalton is slightly above the rule of five; [32] however, according to ar ecent analysis, > 30 %o fa pproved small-molecule kinase inhibitors have am olecular weighte xceeding 500. [33] Pan-CDK inhibitor AT7519
Cyclin-dependent kinases (CDKs) belongt oafamily of serine/ threonine kinases which associatew ith an activating cyclin regulatory subunit. Cell-cycle kinases 1, 2, 4, and 6a re required for the correct timing and order of the eventso ft he cell-division cycle, whereas non-cell-cycle CDKs 7a nd 9a re involved in gene transcription via regulationo fR NA polymerase II activity. Deregulated CDK activity results in the loss of function of cellcycle checkpoints andi ncreased expression of anti-apoptotic proteins,w hich have both been directly linked to the molecular pathology of cancer.S ince their discovery,C DKs have been considered strong prospective targets for an ew generation of anticancer drugs. [34] AT7519 is ap otent, small-molecule multi-CDK inhibitor that has been evaluated in clinicalp hase II trials [35] ( Figure 3 ). AT7519 was discovered using fragment-based medicinal chemistry approaches, linked to high-throughput X-ray crystallography. [36] During lead optimization, introduction of the solubilizing aminopiperidine amide group resulted in improved selectivity for CDKs over other kinases, improved cellulara ctivity, and lower plasma clearance. In the CDK2 co-crystal structure of AT7519, the piperidinyl moiety is pointing out of the ATPb inding pocket, toward solvent. [37] Along the lines of imatinib analogue 8,t he effectso f as witch from the solubilizing 4-aminopiperidine group of AT7519 to the sulfoximine analogue 15 were investigated ( Figure 3 ). The synthesis of analogue 15 involved initial preparation of the sulfoximine building block 12,s tarting from tetrahydro-2H-thiopyran-4-amine( Scheme 3), via the same sequenceoft ransformations as used for the synthesis of building block 4.T hen, amide coupling of amine 12 with commercial acid 13 in the presence of EDCa nd HOBt, followed by deprotectiono fs ulfoximine 14 under basic conditions, afforded the desired compound 15.
With an IC 50 of 522 nm against CDK2 and of 124 nm against CDK9,s ulfoximine analogue 15 exhibited decreased CDK inhibitory activity in vitro relative to AT7519, with an IC 50 of 96 nm against CDK2 and of 6nm against CDK9 (Table 2 ). Both compounds showedp otent antiproliferativea ctivity against A2780 cells in vitro. The higherb iochemical potency of AT7519 translated into ah igher antiproliferativep otencya gainst A2780 cells, with an IC 50 of 131 nm, relative to an IC 50 of 351 nm for analogue 15.
The thermodynamic solubility of AT7519 and analogue 15 in water at pH 6.5 was determined by an equilibrium shake flask method. [38] AT7519 has ah igh aqueous solubility of 1524 mg L
,c omparedt o5 2mgL À1 for sulfoximine 15.U sing reversed-phase HPLC, as lightly increased logD value of 1.6 at pH 7.5 for analogue 15 was recorded, compared to 1.3 for AT7519 ( À1 and ah igh efflux ratio, even though their mo- Figure 3 . Structure of multi-CDK inhibitor AT7519 with its proposed binding mode to CDK2, [37] andstructure of sulfoximine analogue 15. [31] (see Ta ble 6 ).
SelectiveCDK4/6 inhibitors palbocicliband ribociclib
Numerous pharmaceutical companies have initiatedd rug discovery effortst oi dentify low-molecular-weightC DK inhibitors for cancertherapy,but most pan-CDK inhibitors have failed rigorous clinicalt esting so far,a tl east in part because nonselective pan-CDK inhibition is toxic to noncancerous cells. [40] These issues of effectiveness and toxicity seem to have been overcome by the more selectivet argeting of CDK4 and CDK6, ap air of kinases that are similari ns tructure and function, which mediate transition from the G 0 /G 1 -phaset ot he S-phase of the cell cycle. Three of these new CDK4/6 inhibitors (abemaciclib, palbociclib, andr ibociclib) have emerged, followingt he findings of earlyp hase trials, as agents with promising anticancer activity and manageable toxicity. [41] Palbociclib received accelerated FDA approvali n2 015, in the setting of hormone receptor (HR) positive, advanced-stageb reast cancer.I n2 016, ribociclib received FDA breakthrough therapy designation as the first-line treatment for HR + /HER2À advanced breast cancer.
The 2-aminopyrido[2,3-d]pyrimidin-7-onec ore of palbociclib ( Figure 4 ) forms two hydrogen bonds to the kinase hinge region via the pyrimidine N3 nitrogen andt he exocyclic 2-amino group.
[42] Twoa dditional hydrogen bonds, via the pyridine nitrogen of the pyridylaminos ide chain and the acetyl group, orientate the inhibitor in the ATPb inding pocket. The piperazine group of the C2 side chain of palbociclib is directed toward the exit of this ATPb inding pocket. Replacing the piperazineg roup by av ariety of heterocyclic groups resulted in little effect on the bindinga ffinity, [42b] suggesting that the presence of ab ulky group at this position improves inhibitor potency butc ontributesl ittle to kinase selectivity.A saresulto f lead optimization to palbociclib, the piperazinyl substituent of the C2 side chain was considered optimal with regard to potency and physicalp roperties. This structural motif is also found in ribociclib [43] and, in the form of the ethyl analogue, in abemaciclib. [44] Along the lines of imatinib analogue 8,t he effectso f aswitch from the bulky,solubilizing piperazine group of palbociclib and ribociclib to the corresponding sulfoximine analogues 23 and 26 were investigated (Figure 4) . [45] The sulfoximine analogues of palbociclib andr ibociclib were both synthesized using the Boc-protected sulfoximine buildingb lock 19 (Scheme 4). The synthesis of 19 was accomplished in four steps startingf rom thiomorpholine and commercial 5-bromo-2-nitropyridine. Heating these two compounds at 120 8Cf or 1h without solventr esultedi nq uantitative formation of the coupled product 16.S ulfide oxidation to the corresponding sulfoxide 17 was carried out in good yield with aqueous H 2 O 2 , withouts ulfone formation. Direct rhodium-catalyzed imination of 17 with tert-butyl carbamate following the procedure described by Luisi, Bull, and co-workers [9j] gave the Boc-protected 50 valuesd etermined in biochemical in vitrok inasea ssays in the presence of 10 mm ATP. [39] [b] IC 50 values determinedi na ni nvitro proliferation assay using cultivated A2780 cells. [39] [c] Thermodynamic solubility in water determined by an equilibriums hake flaskm ethod; [39] solid state of the testc ompounds was not characterized. [d] Determined by reversed-phase HPLC. [29] [e] Predicted hepatic metabolic clearance based on ahigh-throughputmetabolic stability assayu sing 1) freshly harvestedr at hepatocytes( rHep) and 2) pooled human liver microsomes( hLMs). [30] [f] P app A!B( apicalt ob asolateral) and effluxr atio (ER)d ata were generated in ab idirectionally performedC aco2 permeability assay in a2 4-wellf ormat;E Rw as calculateda sP app B!A/P app A! B. [30] ChemMedChem 2017, 12,487 -501 www.chemmedchem.org 2017 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim sulfoximine 18 in 83 %y ield. Reduction of the nitro group by hydrogenolysis proceeded cleanly to provide the aminopyridine 19 in 68 %yield.
The synthesis of palbociclib analogue 23 was then accomplished via the nucleophilic addition of building block 19 to the commercial chloropyrimidine 20, which gave coupled product 21.S ubsequent Stille coupling with tributyl(1-ethoxyvinyl)tin followed by acid hydrolysis was used to introducea na cetyl group, forming precursor 22,w hich finally was deprotected with TFAt op rovide the desired product 23 (Scheme 5).
The synthesis of ribociclib analogue 26 was completed in two steps from building block 19:p alladium-catalyzed amination of commercialc hloropyrimidine 24,f ollowed by cleavage of the N-Boc protecting group in coupled product 25 under acidic conditions, gave the desired sulfoximine 26 (Scheme6).
In comparison with palbociclib, sulfoximine analogue 23 exhibitedl ower but more balanced inhibitory activity in vitro against CDK4 and CDK6 (Table 3 ). Palbociclib and its analogue 23 both showed potent antiproliferative activity against MOLM-13 cancer cells in vitro, with an IC 50 of 41 nm and of 128 nm,r espectively.P ut side by side, ribociclib was more active than itss ulfoximine analogue 26 against both CDK4 and CDK6. Interestingly,t he difference in antiproliferative activity against MOLM-13 in vitro for the latter pair of compoundsw as quite pronounced, with an IC 50 of 89 nm for ribociclib vs. 1150 nm for 26.
The thermodynamic solubility of palbociclib and analogue 23 in water at pH 6.5, as determined by an equilibrium shake flask method, [38] is very similar( 34 mg L À1 for palbociclib vs. 30 mg L À1 for 23). Using reversed-phase HPLC, [29] as lightly increasedl ogD value of 2.0 at pH 7.5 for analogue 23 was recorded, comparedw ith 1.9 for palbociclib (Table 3) . Relative to ribociclib, sulfoximine analogue 26 also exhibitedaslightly increasedl ogD value;however,the difference in thermodynamic, aqueous solubility at pH 6.5 provedt ob em ore pronounced than the palbociclib matched pair,w ith 334 mg L À1 recorded for ribociclib vs. 22 mg L À1 for 26. In vitro pharmacokinetic studies with palbociclib and analogue 23 again revealed at rend for as lightly improved stability of the sulfoximine analogue in rat hepatocytes,r esulting in al ow predicted CL b of 1.1 Lh À1 kg À1 for sulfoximine 23,c ompared with 1.3 Lh À1 kg À1 for palbociclib. As imilar trend was observed with human liver microsomes (Table 3) . However,i n the Caco2 screening assay,a nalogue 23 had ad ecreased permeability coefficient (P app A!B) of 25 nm s À1 anda ni ncreased efflux ratio of 9.1, relative to palbociclib with apermeability coScheme5.Synthesis of palbociclib analogue 23. Reagentsa nd conditions:a)19 (1 equiv), iPrMgCl( 3.1 equiv),T HF,08C!RT,21h,1 5%;b )tributyl(1-ethoxyvinyl)tin (1.5 equiv), PdCl 2 (PPh 3 ) 2 (8.5 mol %), dioxane, 100 8C, 7h,then HCl, RT,2h; c) TFA( 7equiv), CH 2 Cl 2 ,1h, 64 %( 2steps).
Scheme6.Synthesis of ribociclib analogue 26. Reagents and conditions:a)Pd(OAc) 2 (5 mol %), rac-BINAP(5mol %), Cs 2 CO 3 (1.4 equiv), dioxane,1 10 8C, 6h,7 1%;b )TFA (7 equiv), CH 2 Cl 2 ,R T, 5h,6 7%. [a] IC 50 values determined in biochemical assays at ProQinase, in the presence of 10 mm ATP( CDK4/CycD3) or 30 mm ATP( CDK6/CycD3).
[b] IC 50 valuesd etermined in an in vitro proliferation assay using MOLM-13 cells. [39] [c] Thermodynamic solubility in water determined by an equilibrium shake flask method; [39] solid state of the testc ompounds was not characterized.
[d] Determined by reversed-phase HPLC. [29] [e]Predicted hepatic metabolic clearance based on ah igh-throughput metabolic stability assay using freshly harvestedr at hepatocytes( rHep) and (ii)pooledh umanl iver microsomes (hLMs). [30] [f] P app A!B( apical to basolateral) and efflux ratio (ER) data were generated in ab idirectionallyp erformed Caco2p ermeability assay in a2 4-well format; ER was calculated as P app B!A/P app A!B. [30] ChemMedChem .T he trend for ah igher in vitro metabolic stability of sulfoximine analogue 26 was also observedw ith human liver microsomes. Along the lines of the palbociclib/analogue 23 pair,sulfoximine 26 also hadd ecreased permeability and an increased efflux ratio relative to ribociclib.
Vardenafil
Penile erection is ah emodynamic process initiated by the relaxation of smooth musclei nt he corpus cavernosuma nd its associated arterioles. Nitric oxide,w hich is released from nerve endingsa nd endothelialc ells in the corpus cavernosum during sexual stimulation, activatest he enzymeg uanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP)i nt he smooth muscle cells of the corpus cavernosum. cGMP in turn triggerss mooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs).T he mosta bundant PDE in the human corpus cavernosum is the cGMP-specific phosphodiesterase type 5( PDE5); thus, the inhibition of PDE5 enhances erectile function by increasingt he amounto fc GMP. [46] For the treatment of erectile dysfunction, the differentiation of marketed PDE5 inhibitors based on efficacy is limited, whereas differentiation based on the pharmacokinetic profile (e.g.,l onger half-life and/or faster onset) is possible. [47] Because PDE5 is also present in the arterial wall smooth muscle within the lungs, the PDE5 inhibitors sildenafila nd tadalafil are also FDA-approved for the treatment of pulmonary hypertension.
Sildenafil, the prototypical PDE5 inhibitor ( Figure 5 ), binds to the active site of PDE5 by ac ombinationo fh ydrophobic and polar interactions, in which the hydrophobic interactions dominate. [48] The pyrimidinone ÀNHCOÀ fragment forms ad ual hydrogen bond, while the pyrazole N-methyl group fills as mall hydrophobic pocket, the propyls ubstituent participates in close van der Waals contacts, andt he ethoxy substituent occupies ap ocket with mostly hydrophobic amino acid residues. The methylpiperazine group is exposed at the protein surface through the opening to the active site. Its interactions with the surroundingh ydrophobic residues are not found in the equivalent region of PDE4-ligand complexes and presumably contribute to the selectivityo fs ildenafil for PDE5. Notably,s ildenafil's sulfonyl group, as trong hydrogen-bond acceptor,i s not involved in any hydrogen bonding. [47, 49] Sildenafil and vardenafild iffer in the heterocyclic ring system usedt om imict he purine ring of cGMP and also differ in the substituent at the piperaziner ing (sildenafil:m ethyl, vardenafil:e thyl;F igure 5). However,the higherbiochemical potencyofvardenafil over sildenafilh as been largely attributed to the successful scaffold leap to the different heterocyclic core. [50] To gain further insighti nto the SAR at the piperazine position and to investigate possible implications on the in vitro pharmacokinetic properties, the sulfoximine analogue 29 of vardenafil was prepared in an opportunistic approach. The synthesis of sulfoximine analogue 29 was accomplished in just two steps. Addition of sulfoximine building block 4 (see Scheme1)t ot he commercial sulfonyl chloride 27,f ollowed by removal of the trifluorocarbonyl group at the sulfoximine nitrogen under basic conditions, yielded the desired sulfoximine 29 (Scheme 7).
Gratifyingly,s ulfoximine analogue 29 provedt ob eav ery potent PDE5 inhibitor.W ith an IC 50 of 0.025 nm in the in vitro PDE5 enzyme assay, [51] compound 29 is basically equipotent with vardenafil (IC 50 = 0.029 nm,T able4).
The thermodynamic solubility of vardenafil in water at pH 6.5 is higher than that of analogue 29 (220 mg L À1 for vardenafilv s. 52 mg L À1 for 29). Sulfoximine analogue 29 exhibited as ignificantly decreased logD value of 2.0 relative to 2.6 for vardenafil.
In vitro pharmacokinetic studies with vardenafil and sulfoximine 29 revealed as imilar trend as in the other examples in this study in which an amine was exchanged for as ulfoximine group. Analogue 29 displayed improved in vitro stabilityi nr at hepatocytes and human liver microsomes. However,i nt he Caco2 screening assay,v ardenafil had ah igh permeability coefficient( P app A!B) of2 06 nm s À1 and efflux ratio of 0.87 where- (Table 4) . It can be argued that the TPSA of sulfoximine analogue 29 is not within the Veber rule [52] and, additionally,t hat its molecular weight exceeds the rule of five (see Table 6 ). However,t he extento ft he difference in the in vitro permeability properties of vardenafil and its analogue 29 is still surprising.
Fulvestrant
Although selectivee strogen receptor modulators, such as tamoxifen, or aromatase inhibitors, such as anastrozole,a re the preferred endocrine treatment approach for most patients with HR + breastc ancer, many patients experience disease progression despite this therapy or the tumor becomes therapy-resistant. [53] Fulvestrant ( Figure 6 ) is as teroid-based, selective estrogen receptor degrader( SERD) that both antagonizes and degrades ER-a and is active in patients experiencing disease progression on antihormonal agents.I nc ontrast to some other antitumor agents, sustained exposure to fulvestrant via chronica dministration is required for activity.F ulvestrant is ap articularly lipophilic molecule, even relative to other steroidal compounds, with extremelyl ow aqueous solubility,a ta n estimated 10 ng mL À1 . [54] Therefore, significant research has been conducted on the identification of suitable pharmaceutical formulations.O ral delivery hasbeen explored using ar ange of formulations;h owever,t he low level of bioavailability and presystemic metabolism mean that this is not an appropriate route of administration. [55] Hence, al ong-acting, intramuscular (i.m.) formulation of fulvestrant was developed. Fulvestrant is highly metabolized across species, both in vitro and in vivo. After i.v.o ri .m. delivery in humans, fulvestrant is converted at the 3-and1 7-positionso ft he steroid nucleus to form ketone, sulfate, and glucuronide metabolites, and at the 9'-position to form the sulfone metabolite 30 ( Figure 6 ). [56] To investigate the impact of an exchange from sulfoxide to sulfoximine at the 9'-position on biological activity,p hysicochemistry,a nd in vitro metabolism, the sulfoximine analogue 33 was prepared. This target molecule would also provide an interesting opportunity to evaluate the feasibilityo fn ovel, safe imination procedures when applied to complex compounds. In our experience, the conversion of asulfoxide into asulfoximine can resultinc omplex product mixtures in poor yields involving difficult purification procedures,ore ven that it fails completely, depending on the chemical nature of the startingm aterial. [11] The synthesis of analogue 33 was carried out from commercially available fulvestrant (Scheme 8). Various literature imination procedures [9a, g, 57] were tested in an attempt to directly obtain the sulfoximine in one synthetic step. Unfortunately, these reactions resultedi ni nsufficient conversions and complex product mixtures. We suspected that the unprotected hydroxy groups, especially the phenoxy group, were the root [51] [b] Thermodynamic solubility in water determined by an equilibriums hake flask method; [39] solid stateo ft he test compounds was not characterized.
[c]Determined by reversed-phase HPLC. [29] [d] Predicted hepatic metabolic clearance based on ah igh-throughput metabolic stability assay using 1) freshly harvestedr at hepatocytes (rHep) and 2) pooled humanl iver microsomes (hLMs). [30] [e] P app A!B( apical to basolateral) and efflux ratio (ER)d ata were generated in ab idirectionally performedC aco2 permeability assay in a24-wellformat;ERw as calculated as P app B!A/P app A!B. [30] Scheme8.Synthesis of fulvestrant analogue 33. Reagents and conditions:a)TBSCl (4 equiv),imidazole (10 equiv), DMF,RT, 16 h, 95 %; b) H 2 NCO 2 NH 4 (4 equiv), PhI(OAc) 2 (3 equiv), MeOH,R T, 2h,7 0%;c )TBAF (4.5 equiv), THF,6 08C, 4h,6 8%. cause of these problemsa nd thus both hydroxy groups were protectedw ith TBS (31)i no ne step prior to imination. Althoughk nown rhodium-catalyzed imination methods were employed successfully, [9a, g] the simplicity of the new noncatalytic procedure reportedb yL uisi, Bull, and co-workers, [57] using ammonium carbamate as the iminating agent,d rew our attention. This methoda llowed preparation of the free sulfoximine 32 under mild conditions in a7 0% yield (Scheme 8). Final deprotection of both hydroxy groups with TBAF affordedf ulvestrant analogue 33.
Fulvestrant and its sulfoximine analogue 33 both had very potent in vitro activities in aw ild-type estrogen receptor1 transactivation assay, [58] with an IC 50 of 2.0 nm and of 1.8 nm, respectively.F urthermore, analogue 33 also exhibited very potent antiproliferativea ctivity in vitro against human MCF7 cells stimulated with 17b-estradiol, [59] with an IC 50 of 7.1 nm, very similar to the IC 50 of 9.2 nm for fulvestrant ( Table 5 ).
The switch from sulfoxide to sulfoximinea tt he 9'-position also resulted in as ignificant decreasei nlipophilicity of analogue 33 with al ogD value of 3.8 compared with 4.2 for fulvestrant.H owever,t his did not translate into am easurable improvement in solubility.F ulvestrant and its analogue 33 both have aqueous solubility at pH 6.5 below the detection limit (< 0.1 mg L À1 ), using the equilibrium shake flask method. [38] In contrast to prior examples in this study,s ulfoximine 33 did not display significantly improved in vitro stabilityo ver fulvestrant.Analogue 33 and fulvestrant both have low metabolic stabilityi nr at hepatocytes with ah igh predicted CL b of 3.5 Lh À1 kg
À1
.W ith human liver microsomes, sulfoximine 33 also revealed av ery similars tabilityt of ulvestrant (CL b of 1.2 Lh À1 kg À1 for fulvestrant vs. 1.1 Lh À1 kg À1 for 33,T able 5). Unfortunately,a nalogue 33 also did not showa ny improvement with regard to permeability properties. Both compounds, fulvestranta nd its analogue 33,e xhibited no permeability in either direction (P app A!Ba nd P app B!A) which maya lso be attributable to precipitation and extensive sticking to plastics during the incubation period( 90 min).
Conclusions
After its late discovery, the sulfoximine group garnered only av ery moderate interesti nm edicinal chemistry for many decades. In recent years, however,i nteresti ns ulfoximine chemistry has increased substantially,a se videnced by the development of new,s afe methods for the preparation of sulfoximines, as ignificant increase in life science patent applications incorporating sulfoximine compounds, and the clinicale valuation of at least three novel sulfoximines, the kinase inhibitors roniciclib, BAY1 143572, and AZD 6738. Nevertheless, there remain gaps in the general understanding of this neglected functional group with respect to its medicinal chemistry relevant properties, which still need to be clarified. Very recently,G namm, Bolm, and co-workerse valuated the in vitro properties of as et of sulfoximines and concluded that sulfoximinesd on ot have any "intrinsic flaw" and often exhibit favorable properties compared with other,more established functional groups in medicinal chemistry. [17] Our study also aimed to shed further light on the medicinal chemistry relevant properties of sulfoximines. With this view in mind, we prepared as et of direct sulfoximine analogues of marketed drugs (imatinib, palbociclib, vardenafil, fulvestrant) and advanced clinical candidates (AT7519, ribociclib) to compare the in vitro properties of the matched molecular pairs.
This work could not be expected to deliver ag eneral guideline for chemists in the life sciences as to when the introduction of as ulfoximine group should be considered. This is not only due to the limited number of analogues investigated, but also because our approach was based on an opportunistic, late-stage exchange of one functional group in compounds which had already been thoroughly optimized for the treatment of human diseases. Furthermore, it is known that the overall properties of ac ompound are determined by the "Gesamtkunstwerk" (complete work of art) and not solely by one functional group. Nevertheless, the results from this study contributen ew pieces to the emerging picture of sulfoximinesa s pharmacophores ands upport previous findings that there seemst ob en oi ntrinsic flaw of this neglected functional group. For instance, the metabolic stabilityo fs ulfoximinesw as not identified as an issue in our study.T he analogues of imatinib, palbociclib, ribociclib, and vardenafil all revealed at rend for improved metabolic stabilities in pharmacokinetic studies in vitro, and sulfoximine 15 was significantly more stable in rat hepatocytes and human liver microsomest han its matched pair AT7519. With respect to lipophilicity,v ery similarl ogD valuesw ere recorded for the amines imatinib, AT7519, palbociclib, and ribociclib, and their corresponding sulfoximine analogues ( 8, 15, 23, 26) . Am ore pronounced differencew as noted for the analogueso ft he ethylpiperazine vardenafil and 50 values determined in aw ild-typee strogenr eceptor 1( ESR1) transactivation assay. [58] [b] IC 50 values determined in an in vitro proliferation assay using human MCF7 cells stimulated with 17b-estradiol (E2). [59] [c]Thermodynamic solubility in water determinedb ya ne quilibrium shake flask method; [39] solid state of the testc ompounds was not characterized.
[d] Determined by reversed-phase HPLC. [29] [e] Predicted hepatic metabolicc learanceb ased on ah igh-throughput metabolic stability assayu sing 1) freshly harvestedr at hepatocytes( rHep)a nd 2) pooled human liver microsomes (hLMs). [30] [f] P app A! B(apical to basolateral) and efflux ratio(ER) data weregenerated in abidirectionallyperformedCaco2 permeabilityassay in a24-wellformat;ERwas calculated as P app B!A/P app A!B. [30] ChemMedChem 2017, 12,487 -501 www.chemmedchem.org 2017 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim the sulfoxide fulvestrant. In both cases, the logD value of the sulfoximine analogue (29, 33) w as decreased. In comparison with the amines in this study,t he corresponding sulfoximine analogues do not show superior aqueous solubility at pH 6.5. The matched pair analogues of imatinib and palbociclib have similar solubility,w hereas the analogues of AT7519, ribociclib, and vardenafil have significantly lower solubilitya tp H6.5. The extremelyl ow aqueous solubility of fulvestrant was confirmed in our assay;h owever,t he sulfoximine analogue 33 with its lower logD value does not exhibit an improved aqueous solubility.I ts hould be noted, however,t hat in this study the solid state of the test compounds, which can influence the solubility properties significantly,w as not assessed (e.g.,b yX -ray powderdiffraction).
In contrast to our previousf indings with roniciclib [13b, 14] and BAY1 143572, [15b, c] the current results indicate that permeability and efflux can be an issue when as ulfoximine group is introduced. With the exception of compound 15,a ll analogues in this study displayed decreased permeability and increased efflux. Most striking is the significant loss of permeability and increased efflux that wasr ecorded with the analogue 29 of vardenafil. Unfortunately,t he permeability properties of fulvestrant and its analogue 33 could not be properly assessed due to the very low solubility and high lipophilicity of these compounds. As noted, this investigation used late-stage exchange of af unctionalg roup in optimized compounds, and some of the resulting sulfoximines are borderline with respect to accepted drug-like score rules (Table6); however,our results indicate that the permeability properties of sulfoximiness hould be evaluated early.U se of the corresponding N-methyl sulfoximines may improve the permeability properties. [17] With regardt oi nvitro potency, our resultsa re very promising. The analogues of the kinase inhibitors imatinib, AT7519, and palbociclib all have sub-micromolar activities in the relevant biochemical assays. These compounds also exhibit modulated kinase selectivityp rofiles, which is surprising because the sulfoximine groups are expected to be directed towardt he exit of the kinase binding pockets. The biochemical activity of these compounds also translated into good cellular activities with promising antiproliferativee ffects of sulfoximines 15 and 23 in vitro. Moreover,b oth sulfoximines 29 and 33 displayed at least equipotent activitya sv ardenafil and fulvestrant, respectively,i nt he corresponding biochemical assays. Sulfoximine 33 also had low-nanomolar activity in the cellular antiproliferation assay using MCF7c ells, being at least as potent as fulvestrant.
Overall, these new resultsf urthers upport the earlier recommendation that the sulfoximine moiety be added to the medicinal chemist's toolbox, thus broadening the chemical repertoire in small-molecule drug discovery to tackle biological targets in an even more multifaceted manner. [6] Accordingly,f urther innovations in sulfoximines ynthetic methodology,a long with as ignificant increase in commercials ulfoximine building blocks, would help to accelerate the field of sulfoximines as pharmacophores in the life sciences.
Experimental Section
Commercially available reagents and anhydrous solvents were used without further purification. All air-and moisture-sensitive reactions were carried out in oven-dried (at 120 8C) glassware under an inert atmosphere of argon. Reactions were monitored by TLC and UPLC analysis with aW aters Acquity UPLC MS Single Quad system;c olumn:A cquity UPLC BEH C 18 À1 ;t emperature: 25 8C; DAD scan:2 10-400 nm. Analytical TLC was carried out on aluminum-backed plates coated with Merck Kieselgel 60 F 254 ,w ith visualization under UV light at 254 nm. All NMR spectra were recorded on Bruker Avance III HD spectrometers. 1 HNMR spectra were obtained at 300, 400, 500, or 600 MHz and referenced to the residual solvent signal (7.26 ppm for CDCl 3 ). 13 CNMR spectra were obtained at 101 or 151 MHz and also referenced to the residual solvent signal (77.16 ppm for CDCl 3 ). All spectra were obtained at ambient temperature (22 AE 1 8C).
1
HNMR data are reported as follows:c hemical shift (d)i np pm, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quin = quintuplet, sxt = sextuplet, br = broad, m = multiplet), coupling constant(s) (Hz) , and integration. Mass spectra were recorded on LC-MS instruments:1 )Waters Acquity UPLC MS Single Quad system;c olumn:K inetex 2.6 mm, 50 2.1 mm, or 2) Agilent 1290 UPLC MS 6230 TOFs ystem;c olumn: BEH C 18 1.7 mm, 50 2.1 mm;e luent A: H 2 O + 0.05 %f ormic acid (99 %), eluent B: MeCN + 0.05 %f ormic acid (99 %). Fragment ions are reported as m/z values with relative intensities (%) in parentheses. High-resolution mass spectra were recorded on aX evo G2-XS QTof (Waters) instrument. Melting points were determined with aBüchi B-540 melting point apparatus.
Benzyl thiomorpholine-4-carboxylate (1):Around-bottom flask charged with thiomorpholine (100 g, 969 mmol) and aq. NaOH Table 6 . Molecular weight (MW), topological polar surface area (TPSA), and number of hydrogen-bond donors (HBD) and acceptors (HBA) of the test compounds in this study. [a] HBD:n umber of heteroatoms( O, N, P, S) with one or more attached hydrogen atoms.
[ b] HBA:n umber of heteroatoms( O, N, P, S) with one or more lone pairs, excluding atomsw ith formal positive charges, amide and pyrrole-typen itrogen atoms, and aromatic oxygen and sulfur atoms in heterocyclic rings. (1.0 m,580 mL, 580 mmol) was cooled to 0 8C. Benzyl chloroformate (83 mL, 589 mmol) was added dropwise and the reaction mixture was stirred for 1hat 0 8Ca nd then for 3hat RT.T hen, the mixture was neutralized with aq. HCl (1.0 m)a nd extracted with EtOAc (2 ). The combined organic layer was washed with sat. aq. NaCl, dried (Na 2 SO 4 ), filtered, and concentrated to afford 1 as ab rown oil (138 g, 581 mmol, 98 %):
1 HNMR (300 MHz, CDCl 3 ): d = 7.27-7.42 (m, 5H), 5.14 (s, 2H), 3.71-3.82 (m, 4H), 2.50-2.68 ppm (m, 4H) .
Benzyl thiomorpholine-4-carboxylate 1-oxide (2):T oastirred solution of sulfide 1 (93 g, 392 mmol) in MeCN (928 mL) was added FeCl 3 (1.8 g, 11.2 mmol) and the reaction mixture was stirred for 10 min at RT.T hen, H 5 IO 6 (95.5 g, 419 mmol) was added in three portions. The reaction was slightly exothermic and aw ater bath at % 10 8Cw as used to control the temperature. The starting material was consumed after 3h.T hen, the reaction mixture was added to sat. aq. Na 2 S 2 O 3 (3 L) and stirred for 72 ha tR T. The organic phase was separated and the aqueous layer was extracted with THF (2 ). The combined organic layer was washed with sat. aq. NaCl, dried (Na 2 SO 4 ), filtered, and concentrated to give 2 (107 g, crude): A mixture of 6 (124 mg, 0.29 mmol), crude sulfoximine 4 (100 mg, 0.43 mmol), and Et 3 N( 81 mL, 0.58 mmol) in DMF (1 mL) was held at reflux for 24 h. After cooling, the mixture was concentrated and the residue was dissolved in MeOH (1 mL). K 2 CO 3 (80 mg, 0.58 mmol) was added and the mixture was stirred at RT for 1h before it was diluted with sat. aq. NaCl and extracted with EtOAc (2 ). The combined organic layer was filtered over aW hatman filter and concentrated. (27) , 528 (11) .
Benzyl tetrahydro-2H-thiopyran-4-ylcarbamate (9):Aroundbottom flask charged with tetrahydro-2H-thiopyran-4-amine (50.0 g, 427 mmol) and aq. NaOH (1.0 m,5 00 mL, 500 mmol) was cooled to 5 8C. Benzyl chloroformate (60 mL, 427 mmol) was added dropwise and the reaction mixture was stirred at RT for 1h.T hen, the mixture was extracted with CH 2 Cl 2 (3 ). The combined organic layer was washed with sat. aq. NaCl, dried (Na 2 SO 4 ), filtered, and concentrated. The crude was suspended in hexanes and filtered in aB üchner funnel to afford 9 as aw hite solid (62. Benzyl 1-oxidotetrahydro-2H-thiopyran-4-ylcarbamate (10):T o as tirred suspension of sulfide 9 (62.5 g, 249 mmol) in MeCN (600 mL) was added FeCl 3 (1.13 g, 7mmol), followed by H 5 IO 6 (60 g, 264 mmol) in two portions. The reaction was slightly exothermic and aw ater bath at % 10 8Cw as used to control the temperature. The mixture was stirred at RT for 3hbefore it was added to sat. aq. Na 2 S 2 O 3 and extracted with EtOAc (3 ). The combined organic layer was dried (Na 2 SO 4 ), filtered, and concentrated to give 10 as aw hite solid (66.4 g, 248 mmol, quant.): N-(4-Amino-1-oxo-1l
6 -thian-1-ylidene)-2,2,2-trifluoroacetamide(12):P d/C (10 wt %P d, 78 mg, 0.07 mmol) was added to as olution of sulfoximine 11 (400 mg, 1.06 mmol) in MeOH (38 mL) and THF (19 mL), and the mixture was stirred for 5hat RT under an H 2 atmosphere (1 atm). The mixture was filtered and the filtrate was concentrated to give crude amine 12 (254 mg) that was used without further purification. (21): iPrMgCl (2 m in THF, 0.27 mL, 0.53 mmol) was added dropwise to as uspension of 19 (158 mg, 0.48 mmol) in anhydrous THF (2 mL) at 0 8C. As uspension of commercial chloride 20 (166 mg, 0.48 mmol) in THF (1 mL) was added dropwise to the mixture at 0 8C, which was then stirred at RT for 18 h. Additional iPrMgCl (2 m in THF,0 .24 mL, 0.48 mmol) was added and the mixture was stirred at RT for 1h,b efore additional iPrMgCl (2 m in THF,0 .24 mL, 0.48 mmol) was added, and the mixture was finally stirred for 2h.T he reaction mixture was quenched with aq. HCl (0. , tributyl(1-ethoxyvinyl)tin (24 mL, 0.071 mmol), and PdCl 2 (PPh 3 ) 2 (2.7 mg, 0.004 mmol) in anhydrous dioxane (0.5 mL) was heated at 100 8C under argon for 7h.A fter cooling, 2drops of aq. HCl (2 m)w ere added and the mixture was stirred at RT for 2h.T he mixture was diluted with CH 2 Cl 2 ,d ried (Na 2 SO 4 ), filtered, and concentrated. The residue was dissolved in CH 2 Cl 2 (3 mL) and trifluoroacetic acid (24 mL, 0.33 mmol) was added. The reaction mixture was stirred at RT for 1hbefore sat. aq. NaHCO 3 was added. The mixture was extracted with CH 2 Cl 2 (2 )a nd the combined organic layer was dried (Na 2 SO 4 ), filtered, and concentrated. (26):T rifluoroacetic acid (69 mL, 0.9 mmol) was added dropwise to as olution of 25 (75 mg, 0.13 mmol) in CH 2 Cl 2 (0.3 mL) and the reaction mixture was stirred at RT for 5h.S at. aq. NaHCO 3 was added and the mixture was extracted with CH 2 Cl 2 (2 ). The combined organic layer was dried (Na 2 SO 4 ), filtered, and concentrated. -thiomorpholin-1-one (29) :Asolution of commercial sulfonyl chloride 27 (140 mg, 0.34 mmol), amine 4 (83 mg, 0.36 mmol), and Et 3 N( 50 mL, 0.36 mmol) in CH 2 Cl 2 (3 mL) was stirred at RT for 24 h. The reaction mixture was diluted with sat. aq. NaCl and extracted with CH 2 Cl 2 (2 ). The combined organic layer was filtered through aW hatman filter and concentrated. The residue was dissolved in MeOH (5 mL) and solid K 2 CO 3 (83 mg, 0.60 mmol) was added. The resulting suspension was stirred at RT for 90 min before it was diluted with sat. aq. NaCl and extracted with CH 2 Cl 2 (2 ). The combined organic layer was filtered through aW hatman filter and concentrated. (31):Asolution of TBSCl (1.02 g, 6.6 mmol) in DMF (5 mL) was added to asolution of imidazole (1.12 g, 16.5 mmol) in DMF (5 mL) at 0 8C. The ice bath was removed and the mixture was stirred for 10 min at RT.A solution of fulvestrant (1.00 g, 1.65 mmol) in DMF (5 mL) was added and the reaction mixture was stirred at RT overnight. The mixture was concentrated and the residue was treated with sat. aq. K 2 CO 3 (10 mL) before it was extracted with CH 2 Cl 2 (4 ). The combined organic layer was dried (Na 2 SO 4 ), filtered, and concentrated. The residue was purified by chromatography (hexane/ EtOAc, 2:8) to give 31 as ac olorless sticky oil (1.31 g, 1.57 mmol, 95 %): R f = 0.46 (hexane/EtOAc, 1:1);
